PureTech Health (LON:PRTC) Shares Up 14.2% - Here's What Happened

Key Points

• PureTech Health shares surged by 14.2% to GBX 121.50 ($1.64) following a substantial increase in trading volume, exceeding average daily volumes by 1,053%.
• The company has a robust current ratio of 3.68 and a debt-to-equity ratio of 45.82, indicating financial stability.
• Insider Bharatt Chowrira purchased 167,739 shares at £1 per share, showcasing confidence in the company's prospects.

PureTech Health plc (LON:PRTC - Get Free Report) shares rose 14.2% during mid-day trading on Saturday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares changed hands during mid-day trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Price Performance

The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The stock's fifty day moving average is GBX 129.46 and its 200-day moving average is GBX 129.76. The stock has a market cap of £293.65 million, a PE ratio of 714.71 and a beta of 1.02.

Insider Activity

In related news, insider Bharatt Chowrira bought 167,739 shares of the stock in a transaction on Thursday, July 3rd. The stock was bought at an average price of GBX 1 per share, with a total value of £1,677.39. Corporate insiders own 13.13% of the company's stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.